# A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study Comparing the Efficacy and Safety of Cofrogliptin Versus Acarbose in Drug-Naïve Patients With Type 2 Diabetes

> **NCT07122102** · NA · NOT_YET_RECRUITING · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Cofrogliptin
- **DRUG:** Acarbose

## Key facts

- **NCT ID:** NCT07122102
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-07-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07122102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07122102, "A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study Comparing the Efficacy and Safety of Cofrogliptin Versus Acarbose in Drug-Naïve Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07122102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*